The purpose of this study is to determine whether magnetic resonance (MR)-proton density fat fraction (PDFF) estimate of negligible hepatic fat percentage (<5%) can exclude significant hepatic steatosis (!10%) in living liver donor candidates obviating the need for liver biopsy and to perform intraindividual comparisons between MR-PDFF techniques for hepatic steatosis quantification. In an ethics-approved retrospective study, 144 liver donor candidates with magnetic resonance spectroscopy (MRS) and 6-echo Dixon magnetic resonance imaging (MRI) between 2013 and 2015 were included. A subset of 32 candidates underwent liver biopsy. Hepatic fat percentage was determined using MR-PDFF and histopathology-determined fat fraction as the reference standard. A receiver operating characteristic analysis with positive predictive value, negative predictive value (NPV), sensitivity, and specificity was performed to discriminate between clinically significant steatosis (!10%) or not (<10%) at MRS-PDFF and MRI-PDFF thresholds of 5% and 10%. Pearson correlation and Bland-Altman analyses between MRS-PDFF and MRI-PDFF were performed for intraindividual comparison of hepatic steatosis estimation. There was significant association between MRS-PDFF and MRI-PDFF with HP-FP. High NPV of 95% (95% confidence interval [CI], 78%-99%) and 100% (95% CI, 76%-100%) as well as an area under the curve of 0.90 (95% CI, 0.79-1.0) and 0.93 (95% CI, 0.84-1.0) were obtained with a cutoff threshold of 5% MRI-PDFF and MRS-PDFF, respectively, to exclude clinically significant steatosis (!10%). Intraindividual comparison between MRS-PDFF and MRI-PDFF showed a Pearson correlation coefficient of 0.83. Bland-Altman analysis showed a mean difference of 1% with 95% limits of agreement between 21% and 3%. MR-PDFF estimate of negligible hepatic fat percentage (<5%) has sufficient NPV for excluding clinically significant hepatic steatosis (!10%) in living liver donor candidates obviating the need for liver biopsy. It may be sufficient to acquire only the multiecho Dixon MRI-PDFF for hepatic steatosis estimation.
liver disease given the shortage of cadaveric liver graft availability. Prevalence rates of hepatic steatosis of 10%-25% have been described among living donors. (1, 2) The presence of hepatic steatosis in the donor liver has important ramifications in terms of recipient outcome as well as donor safety. Among recipients, severe hepatic steatosis in the transplant liver is associated with increased early mortality and risk of ischemia/reperfusion injury as well as increased likelihood of hepatic dysfunction and renal failure. (3) In donors, even mild steatosis has been associated with transient cholestasis (4) and abnormal liver enzyme profiles (5) following partial hepatectomy, whereas livers without significant hepatic steatosis have been shown to have better early regeneration following partial hepatectomy. (4) Abbreviations: AUC, area under the curve; BMI, body mass index; CAI-PIRINHA, controlled aliasing in parallel imaging results in higher acceleration; CI, confidence interval; FF, fat fraction; HISTO, high-speed T2-corrected multicecho; HP-FF, histopathology-determined fat fraction; IDEAL, iterative decomposition of water and fat with echo asymmetry and least-squares estimation; MR, magnetic resonance; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NPV, negative predictive value; PACS, picture and archiving communication systems; PDFF, proton density fat fraction; PPV, positive predictive value; ROC, receiver operating characteristic; ROI, region of interest; STEAM, Stimulated Echo Acquisition Mode; TE, echo time; TR, repetition time.
Even though there is consensus on the risks posed by hepatic steatosis to both donor and recipient, there is variability between institutions on the degree of donor hepatic steatosis that results in donor ineligibility. Although hepatic steatosis of <5% (as determined by biopsy) is considered normal or negligible, some centers (including ours) use < 10% hepatic steatosis as acceptable for liver donation. (6, 7) Other centers have reported exclusion thresholds as high as 20% (8) and 30%. (9) At this time, liver biopsy is regarded as the reference standard for the assessment of hepatic steatosis. However, there is variability among transplant centers on the exact role of pretransplant biopsy in donor evaluation. (10) Some centers perform liver biopsy on all or almost all potential donors, (11) (12) (13) whereas others perform it in select donors with clinical risk factors, high body mass index (BMI), or abnormal liver biochemistry. (10) Regardless of the indication, liver biopsy is also subject to certain limitations inclusive of risks and complications of any invasive procedure which can even include death, (14) sampling errors due to assessment of a very small volume of the liver, (15) and interobserver variability resulting from subjective visual assessment of intracellular lipid droplets. (16) Magnetic resonance imaging (MRI) is an accurate noninvasive quantitative method for hepatic steatosis given its ability to decompose hepatic parenchymal signals into water and fat components. (17, 18) Proton magnetic resonance spectroscopy (MRS) has been studied and validated for assessing for hepatic steatosis. (19) (20) (21) Dual echo chemical shift MRI originally described by Dixon (22) has also been studied extensively but is susceptible to T Ã 2 effects which can lead to underestimation of hepatic fat. (17, 23) More recently, multiecho modified Dixon techniques with estimation of proton density fat fraction (PDFF) have been developed to allow for correction of T Ã 2 decay and other confounding factors. (24) (25) (26) MRI has already been used in donor assessment for examining hepatic vascular and biliary anatomy. (27) A few studies have examined the role of MRI-based fat quantification in potential liver donors with a view to adopt a more selective role for liver biopsy. (8, (28) (29) (30) (31) However, to our knowledge, no studies have been published to support the role of MR fat quantitation techniques that would allow total replacement of liver biopsy in potential liver donors.
Although exclusion thresholds of fraction hepatic steatosis may vary between institutions, the absence or negligible levels of hepatic steatosis (<5%) would be considered universally acceptable for liver donation. (4) To this end, we primarily sought to determine if MRIbased fat quantitation had sufficient negative predictive value (NPV) for exclusion of clinically significant hepatic steatosis that would render liver biopsy unnecessary in potential liver donors. A secondary aim of our study was to perform intraindividual comparison between multiecho Dixon MRI and MRS techniques for hepatic steatosis quantification in this cohort.
Patients and Methods

PATIENTS
Local institutional ethics board approval was obtained for this retrospective study, and the need for consent was waived. A total of 144 consecutive liver donor candidates were identified in the electronic medical record with having had an MRI examination with MRS and/ or MRI-PDFF estimation in a 2-year period between December 2013 and December 2015 at our institution as part of our comprehensive donor assessment protocol. All patients with MRI examinations with fat quantification sequences in that time period were found to have magnetic resonance (MR) studies of sufficient quality for inclusion in this study. At our institution, ultrasound-guided percutaneous liver biopsy was performed in potential liver donors who had either abnormal liver function tests, BMI > 30 kg/m 2 , or evidence of steatosis on any prior imaging. Of the 144 donor candidates, a subset of 32 patients were identified with having had biopsy for the previously mentioned indications.
MR TECHNIQUE Both 1.5T and 3.0T systems (Siemens Avanto fit and Verio fit, Siemens Healthcare, Erlangen, Germany) were used. At our institution, the allocation of patients to either machine is determined based on availability, and no specific MRI systems are intentionally selected for scheduling. MR examinations were performed with the patients in the supine position using 16 or 32 channel phased array torso coils.
MAGNETIC RESONANCE SPECTROSCOPY
MRS was performed using a high-speed T 2 -corrected multiecho (HISTO) 1 H spectroscopy sequence. This involves a series of 5 single-voxel Stimulated Echo Acquisition Mode (STEAM) sequences concatenated with a fixed repetition time (TR) of 3000 milliseconds with acquired echo times (TEs) of 12, 24, 36, 48, and 72 milliseconds. The fat (1.3 ppm) and water (4.7 ppm) peaks were detected for each TE, and the integral of the signal of each peak was determined. An exponential fit was computed using the 5 TEs, which was then used to extrapolate the fat signal integral for TE 0. The MRS-PDFF was calculated as the signal integral of fat divided by the sum of the signal integral of water and fat. Using 3 plane-localizing images, a single 3 3 3 3 3 cm voxel was placed in a homogeneous region of the liver with care to avoid vascular and biliary structures as well as liver margins being at least 2 cm away from the voxel boundary. MRS was performed by an experienced MR technologist.
MAGNETIC RESONANCE IMAGING
Axial images were acquired through the liver using a gradient-recalled echo sequence with a flip angle 4.0 8 and TR of 9.0 milliseconds. Our multiecho Dixon sequence used 6 fractional echoes (6-echo Dixon), which were obtained at echo times 1.05, 2.46, 3.69, 4.92, 6.15, and 7.38 milliseconds in a single breathhold. Other imaging parameters included the following: 3.5-mm slice thickness; 1.4 3 1.4 cm pixel size; 64 slices covering the whole liver; 1 average, parallel imaging factor 4 (controlled aliasing in parallel imaging results in higher acceleration [CAIPIRINHA]), bandwidth 1080 Hz/pixel, and rectangular field of view adjusted to body habitus. This pulse sequence has incorporated complex-based analysis to obtain PDFFs (MRI-PDFF) through inclusion of corrections for confounding factors of T 1 bias, T 2 bias, and T Ã 2 decay; multiple fat spectra; noise bias; eddy currents; and J coupling. (17) Multisection fat fraction (FF) maps were reconstructed from all 6 echoes on a pixel-by-pixel basis by postprocessing software integrated into the scanner and then sent to picture and archiving communication systems (PACS).
IMAGE ANALYSIS
The FF map derived from the multiecho Dixon sequence consisting of 6 echoes was analyzed on a PACS workstation. MRI-PDFF was quantified by placing a large (!2.0 cm 2 ) elliptic region of interest (ROI) on the MRI FF map in a homogeneous region of liver with care to avoid vascular and biliary structures. The yielding mean and standard deviation for the FF within that ROI were recorded in units of percent (%) for each liver. The MRS-PDFF was recorded from the report generated by the HISTO sequence online.
HISTOLOGIC ANALYSIS
Areas of macrovesicular steatosis obtained from the biopsy sample were used for histologic analysis. The degree of macrovesicular steatosis was determined as the fraction of hepatocytes that contained intracellular macrovesicular fat droplets at hematoxylin-eosin staining. An experienced pathologist quantified the degree of steatosis in increments of 5% starting from 0%, and this was designated as the histopathology-determined fat fraction (HP-FF) in our analysis. The reported values for steatosis were obtained from the electronic patient record. Routinely, hepatic steatosis is typically graded on a 0-3 scale based on the number of cells with intracellular vacuoles of fat as follows: grade 0 (normal) 5 up to 5% of cells affected; grade 1 (mild) 5 5%-33% of cells affected; grade 2 (moderate) 5 34%-66% of cells affected; and grade 3 (severe) 5 67% or greater of cells affected. (32) 
STATISTICAL ANALYSIS
Receiver operating characteristic (ROC) analysis was used to evaluate the ability of MRS-PDFF and MRI-PDFF to discriminate between clinically significant (!10%) versus nonsignificant (<10%) HP-FF. The area under the curve (AUC) and corresponding 95% confidence interval (CI) was computed. The positive predictive value (PPV) and NPVs as well as corresponding 95% CI for each MRI-PDFF and MRS-PDFF were calculated for PDFF thresholds set at 5% as well as 10% to determine the optimal threshold for identifying clinically significant steatosis. Sensitivity and specificity with 95% CI were also computed similarly. Correlation between MRI-PDFF and MRS-PDFF was examined by generating the Pearson correlation coefficient. Bland-Altman analysis was used to characterize the agreement between MRI-PDFF and MRS-PDFF. Statistical analyses were performed using SPSS, version 20.0 (IBM Corp., Armonk, NY).
Results
For this study, 32 potential liver donors were identified with biopsy-determined HP-FF obtained within an average of 30 6 35 days of their MRI study. Patient characteristics within this group are summarized in Table 1 . HP-FF values ranged from 0% to 40% with a mean of 6% 6 9%. Values for MRI-PDFF ranged from 2% to 15% with a mean of 6% 6 4%, whereas MRS-PDFF ranged from 1% to 52% with a mean of 7% 6 11%.
An ROC analysis was performed demonstrating an AUC of 0.90 for MRI-PDFF and 0.93 for MRS-PDFF for distinguishing between clinically significant (designated as ! 10% on histopathology at our institution) and nonsignificant HP-FF ( Figs. 1 and 2 ). Predictive values were then computed for distinguishing between clinically significant and nonsignificant HP-FF using MRI-based fat quantification methods (MRI and MRS) for thresholds set at 5% as well as 10% to determine the optimal threshold for identifying clinically significant steatosis of HP-FF ! 10%. When a threshold of 5% was used for the MRI-based methods, high NPVs of 95% (95% CI, 78%-99%) and 100% (95% CI, 76%-100%) were obtained using MRI and MRS, respectively (Table 2 ). Lower NPVs were noted when the same analysis was performed using a cutoff threshold value of 10% for MRS-PDFF and MRI-PDFF (Table 2 ). Modest PPVs were demonstrated for identifying HP-FF ! 10% for both thresholds. The less-than-perfect NPV of 95% obtained using a MRI-PDFF 5% threshold was due to a single subject. This donor candidate was found to have had an HP-FF of exactly 10% on biopsy but was determined to have a MRI-PDFF of 4% and an MRS-PDFF of 6%.
Modest sensitivity was noted for MRI/MRS-PDFF thresholds of 10% for identifying individuals with HP-FF ! 10%. However, this was found to improve when a threshold of 5% was used for the MR-based methods. Good specificity was noted for both MRI/MRS-PDFF thresholds of 5% and 10% without significant difference between the 2 thresholds. (Fig.  3) . Bland-Altman analysis was also performed revealing a mean difference (MRI-PDFF minus MRS-PDFF) of 1% (Fig. 4) and 95% limits of agreement between -1% and 3%. No significant changes in difference were noted with increased magnitude of measured FFs. For example, the largest MRS-PDFF of 28% and MRI-PDFF of 27% was measured in the same patient revealing a difference of 1%.
Discussion
Our study validates the use of MRS and multiecho Dixon MRI (6 echoes in our study) in the evaluation of potential living liver donors for hepatic steatosis estimation, which would have clinically significant consequences for donor eligibility. Using histopathology as a reference standard, we established the ability of MRS and MRI to distinguish between donors without and with significant (!10%) hepatic steatosis. Specifically, we were able to establish very high to perfect NPVs for MRI (95%) and MRS (100%) to exclude the presence of hepatic steatosis !10%, which is considered beyond a safe margin for transplantation at our institution. Our institutional threshold of 10% would be considered more conservative because thresholds as high as 20% or 30% have been reported at some centers (9) over concerns of overrestricting the liver donor pool. The robust performance of MRS and MRI in our study for the relatively conservative threshold of 10% would only be expected to improve at institutions where higher levels of hepatic steatosis are considered acceptable. Some previous studies that have examined the role of MRI in hepatic steatosis estimation with MRI in potential liver donors have had similar results. Hwang et al. (28) reported high sensitivity and specificity with the use of MRS and triple-echo Dixon for the detection of substantial (!10%) hepatic steatosis among donors. Yoon et al. (30) using a multiecho iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) MRI sequence reported very high NPVs of up to 98% to exclude substantial (also defined as ! 10%) hepatic steatosis among donors. Interestingly, as noted in our study, they reported low PPVs with MRI for the detection of hepatic steatosis. Joe et al. (29) and Chiang et al. (33) also used IDEAL-reported high specificity and sensitivity of MRI for the detection of hepatic steatosis among donors with a more restrictive threshold of >5%. To our knowledge, only 3 studies have examined the use of multiecho Dixon techniques for the assessment of hepatic fat among donor candidates. (29, 30, 33) A number of earlier studies have also validated the role of MRI in noninvasive hepatic steatosis quantification outside of the transplant assessment setting. (34) (35) (36) (37) Van Werven et al. (34) demonstrated high sensitivity and specificity of MRI and MRS-PDFF for identifying hepatic steatosis among patients undergoing liver resection with a histopathology cutoff value of 5%. Tang et al. (35) showed relatively high AUCs for distinguishing steatosis grades in patients with nonalcoholic fatty liver disease.
In our study, we observed that a cutoff value of <5% for MRS-PDFF and MRI-PDFF produced the most robust NPVs for excluding HP-FF ! 10%. This difference in scale between MRS-PDFF/MRI-PDFF and HP-FF was also noted in other studies. (28, 32) This difference is not unexpected because MRI provides a relative measure of fat proton signal, whereas HP-FF is based on a visual assessment of the fraction of hepatocytes containing intracellular macrovesicular fat droplets. The small difference in NPV between MRI and MRS (95% versus 100%) was due to a single donor with HP-FF of 10% at exactly the threshold of clinically significant steatosis. The subject was noted to have an MRS-PDFF of 6% and MRI-PDFF of 4%. Although the FF values obtained with the 2 MR methods were only different by 2%, our cutoff threshold FF of 5% resulted in a positive result for MRS and a negative result for MRI. We also noted a period of 22 days between the patient's MR evaluation and biopsy.
We also observed that a cutoff value of 5% for MRS-PDFF and MRI-PDFF produced a demonstrable improvement in sensitivity for identifying HP-FF ! 10% compared with a cutoff value of 10%. The specificity did not change significantly between the 2 cutoff values.
The overall goal of our study was to identify a noninvasive test with high enough NPV to obviate the need for liver biopsy in donors with hepatic FF that is below the threshold for eligibility for transplant at our institution. Our study supports that with the inclusion of MRS and/or MRI 6-echo Dixon sequences, a liver biopsy could be excluded in potential donors with MRS-PDFF or MRI-PDFF of < 5%. With the reported prevalence rate of hepatic steatosis of 10%-25%, (1, 2) this could result in a substantial reduction in unnecessary biopsy among potential donors. Candidates found to have >5% FF on MRI could potentially either undergo biopsy or dietary modification followed by a repeat MRI assessment. This would also obviate the need for multiple biopsies.
We also demonstrated high concordance between FFs obtained by using MRS and MRI with 6-echo Dixon (Pearson correlation coefficient, 0.83) in a larger group of donor candidates. We also noted a low mean difference between MRS-PDFF and MRI-PDFF of 1% with Bland-Altman analysis. This result would suggest that it is very unlikely for a donor candidate to have a substantially different MRS-PDFF and MRI-PDFF so as to have a significant impact with respect to donor eligibility. Therefore, we believe that the use of a 6-echo Dixon MRI sequence alone is sufficient for exclusion of significant steatosis in the liver donor population and that an additional MRS sequence would be redundant in the pretransplant donor assessment MRI protocol. Although MRS has been studied and validated extensively for quantifying hepatic fat, it is subject to sampling limitation in a similar way as biopsy. Additionally, MRS is more technically complex requiring specific expertise and is limited in availability compared with Dixon-based chemical shift methods. (39) Our study has a number of limitations. This was a retrospective, single-center study limited by a small sample size of living liver donor candidates. The majority of our study population had <10% HP-FF, which limits assessment of donors with significant hepatic steatosis. This may also account for the relatively low PPVs obtained in our analysis. However, our study population is representative of the general population as a whole, and our results would be applicable to other transplant centers. A number of candidates had a relatively long time interval between biopsy and MR examinations with a mean of 30 days between biopsy and imaging. Although this may have had an effect on our analysis, a time gap of this magnitude between pretransplant assessment and actual transplant is not uncommon in clinical practice. There was no spatial coregistration between the site of biopsy and MRS-PDFF measurement, which may have implications in the setting of spatially heterogeneous steatosis. Our analysis also did not account for the effects of hepatic iron content and fibrosis. However, considering that the patients are healthy individuals who are worked up extensively, the prevalence of coexistent hepatic iron overload and/or fibrosis can be assumed to be negligible. Our potential liver donor cohort was imaged using either 1.5T or 3T MRI systems with allocation of donors to either machine determined based on availability, and we did not investigate the impact of MRI field strength on hepatic steatosis quantification. However, previous work has shown that MRI-based measurement of hepatic fat is reproducible across MRI field strengths. (40) In conclusion, we have shown that MRI quantification of hepatic steatosis by multiecho Dixon and/or MRS techniques provides very high to perfect NPV to exclude clinically significant hepatic steatosis (!10%) in living liver donor candidates. This obviates the need for liver biopsy in this cohort when MRI-based hepatic quantification results imply absence or negligible hepatic steatosis (<5%). Furthermore, given no significant differences in hepatic FF estimation by multiecho Dixon MRI and MRS techniques, it may be sufficient to acquire only the multiecho Dixon MRI technique for hepatic steatosis quantification.
